Telix to acquire ITM for $1.65B upfront plus up to $700M
Telix Pharmaceuticals said it will acquire 100% of ITM for $1.65B upfront and up to $700M in milestone payments tied to ITM-11 approvals and sales, subject to approvals. Closing is expected by end FY 2026.